Cryo-Cell International, Inc. CCEL
AMEX
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.96% | -2.69% | -2.56% | -1.31% | -0.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.96% | -2.69% | -2.56% | -1.31% | -0.29% |
| Cost of Revenue | 51.66% | 47.66% | 46.78% | 49.43% | -39.23% |
| Gross Profit | -17.91% | -18.39% | -18.32% | -17.83% | 23.20% |
| SG&A Expenses | 0.40% | -0.60% | -1.24% | -2.13% | 4.03% |
| Depreciation & Amortization | -3.56% | -4.52% | 15.76% | 55.40% | 34.31% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.82% | 10.86% | 10.72% | 10.24% | -14.26% |
| Operating Income | -95.62% | -102.72% | -95.24% | -87.27% | 3,119.40% |
| Income Before Tax | -231.40% | -254.77% | -210.11% | -183.35% | 111.76% |
| Income Tax Expenses | -98.08% | -104.48% | -105.61% | -96.16% | 156.31% |
| Earnings from Continuing Operations | -310.81% | -1,340.60% | -2,169.18% | -704.15% | 94.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -310.81% | -1,340.60% | -2,169.18% | -704.15% | 94.70% |
| EBIT | -95.62% | -102.72% | -95.24% | -87.27% | 3,119.40% |
| EBITDA | -78.17% | -81.89% | -75.96% | -67.26% | 734.21% |
| EPS Basic | -311.05% | -1,331.31% | -2,250.00% | -734.24% | 94.51% |
| Normalized Basic EPS | -179.20% | -231.40% | -186.43% | -176.36% | 341.50% |
| EPS Diluted | -241.38% | -904.22% | -3,775.00% | -776.51% | 93.40% |
| Normalized Diluted EPS | -179.81% | -233.74% | -188.56% | -178.54% | 329.81% |
| Average Basic Shares Outstanding | -0.18% | -0.21% | -0.25% | -0.76% | -1.40% |
| Average Diluted Shares Outstanding | -0.72% | -1.00% | -1.11% | -1.05% | -1.67% |
| Dividend Per Share | -100.00% | -100.00% | -70.00% | 60.00% | -- |
| Payout Ratio | 1.00% | 1.00% | -1.01% | -1.26% | -- |